Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2003;42:103-109
Published online before print June 16, 2003, doi: 10.1161/01.HYP.0000077984.85616.23
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
42/1/103    most recent
01.HYP.0000077984.85616.23v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, J. Y.H.
Right arrow Articles by Chan, S. H.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, J. Y.H.
Right arrow Articles by Chan, S. H.H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLUTAMIC ACID HYDROCHLORIDE
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Physiological and pathological control of gene expression
Right arrow Autonomic, reflex, and neurohumoral control of circulation

(Hypertension. 2003;42:103.)
© 2003 American Heart Association, Inc.


Scientific Contributions

Downregulation of Angiotensin Subtype 1 Receptor in Rostral Ventrolateral Medulla During Endotoxemia

Julie Y.H. Chan; Ling-Lin Wang; Chen-Chun Ou; Samuel H.H. Chan

From the Department of Medical Education and Research, Kaohsiung Veterans General Hospital (J.Y.H.C., L.L.W., C.C.O.), and Center for Neuroscience, National Sun Yat-sen University (S.H.H.C.), Kaohsiung, Taiwan, Republic of China.

Correspondence to Samuel H.H. Chan, PhD, Center for Neuroscience, National Sun Yat-sen University, Kaohsiung 804, Taiwan, Republic of China. E-mail: schan{at}mail.nsysu.edu.tw


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
We reported recently that an upregulation of the inducible nitric oxide synthase (iNOS) in the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons are located, is a crucial determinant for the elicitation of cardiovascular depression during experimental endotoxemia. The current study evaluated the hypothesis that a downregulation of the molecular synthesis and functional expression of angiotensin subtype 1 receptor (AT1R) in the RVLM is consequential to this upregulated iNOS. In adult Sprague-Dawley rats maintained under propofol anesthesia, intravenous administration of Escherichia coli lipopolysaccharide (15 mg/kg) elicited a reduction, followed by an augmentation and a secondary decrease in sympathetic vasomotor outflow, together with progressive hypotension and bradycardia. There was also a progressive increase in iNOS mRNA and protein level in the ventrolateral medulla. This was followed by a significant downregulation of both mRNA and protein levels of AT1R in the ventrolateral medulla, alongside reduced efficacy of angiotensin II (50 pmol) to induce an increase in systemic arterial pressure, heart rate, or sympathetic vasomotor outflow on unilateral microinjection into the RVLM. Pretreatment with microinjection of a selective iNOS inhibitor, S-methylisothiourea (250 pmol) bilaterally into the RVLM significantly reversed the reduction in both synthesis and activity of AT1R. We conclude that a downregulation of molecular synthesis and functional expression of AT1R in the ventrolateral medulla is consequential to the overproduction of NO through upregulation of iNOS in the RVLM and may underlie the cardiovascular depression that takes place during experimental endotoxemia.


Key Words: receptors, angiotensin • nitric oxide synthase • central nervous system • hypotension • bradycardia • nervous system, sympathetic


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Sepsis is associated with profound cardiovascular abnormalities characterized by hypotension, decreased systemic resistance, altered vascular reactivity to contractile agents, and a high mortality rate.1 One well-known mediator of sepsis-induced circulatory failure is nitric oxide (NO) produced through activation of the inducible NO synthase (iNOS) in macrophages at the peripheral vasculature.2,3 In addition, we reported recently4 that overproduction of NO by iNOS in the rostral ventrolateral medulla (RVLM) is also a crucial determinant for the reduction in sympathetic vasomotor outflow and fatal cardiovascular depression during experimental endotoxemia. Whereas we proposed that the underlying mechanisms include formation of the cytotoxic substance peroxynitrite5 and activation of GABAergic neurotransmission,6 the possibility exists for the engagement of other mediators in the RVLM.

As the medullary site of the sympathetic premotor neurons,7 the RVLM maintains arterial pressure by providing a tonic excitation to preganglionic sympathetic neurons in the spinal cord.7,8 It is also a target site where the brain renin-angiotensin system acts to regulate sympathetic outflow. Microinjection of angiotensin II (ANG II) into the RVLM elicits an increase in systemic arterial pressure (SAP) and sympathetic activity.9,10 Of the 2 subtypes of ANG II receptors,11 it is generally accepted that activation of the angiotensin subtype 1 receptor (AT1R) in the RVLM contributes mainly to the sympathoexcitatory effect of ANG II.12 Recent studies further suggest that this excitatory angiotensinergic action on sympathetic premotor neurons in the RVLM is tonically active under normotensive13,14 or hypertensive15 conditions.

Several reports16–18 showed that NO antagonizes the biological functions of ANG II. For example, NO reduces ANG II receptor binding sites or AT1R gene expression in smooth muscle cells.16,17 Of particular note is that NO downregulates AT1R and inhibits ANG II–induced migration of vascular smooth muscle cells during sepsis.18 It follows that a downregulation of the molecular synthesis and functional expression of AT1R in the RVLM induced by the overproduction of NO through iNOS activation may underlie the reduction in sympathetic vasomotor outflow during sepsis. The present study validated this hypothesis, based on an animal model of experimental endotoxemia.4


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Animals
Eight-week-old male Sprague-Dawley rats (n=338) purchased from the Experimental Animal Center, National Science Council, Taiwan, were used. All experimental procedures were approved by our institutional animal care committee.

General Preparation
Rats received during the experiment continuous intravenous infusion of propofol (30 mg · kg-1 · h-1), which provided satisfactory anesthetic maintenance while preserving the capacity of central cardiovascular regulation.19 Pulsatile and mean systemic arterial pressure (MSAP) as well as heart rate (HR) were recorded on a polygraph (Gould RS3400).4–6,19,20 Animals were mechanically ventilated to maintain end-tidal CO2 to be within 4% to 5%, as monitored by a capnograph (Datex Normocap). All data were collected from animals with a maintained rectal temperature of 37±0.5°C.

Evaluation of Sympathetic Vasomotor Tone
The SAP signals were simultaneously subject to on-line power spectral analysis.4–6,19–21 We were particularly interested in the very low-frequency (0 to 0.25 Hz) and low-frequency (0.25 to 0.8 Hz) components in the SAP spectrum. Our laboratory demonstrated previously20 that these spectral components of SAP signals take origin from the RVLM, and their power density reflects the prevailing sympathetic neurogenic vasomotor tone.4–6,19–21

Microinjection of Test Agents Into the RVLM
Bilateral microinjection of test agents with the use of a glass micropipette, at a volume of 50 nL, was carried out stereotaxically and sequentially into functionally identified RVLM sites as detailed previously.4–6,21 Each animal received a single injection of a selective iNOS inhibitor,22 S-methylisothiourea (SMT; Tocris Cookson), together with multiple doses of ANG II (Sigma) or L-glutamate (Sigma). The doses used were the same as in our recent studies4–6,21–24 when these test agents were used for the same purpose as in the current study. Microinjection of artificial cerebrospinal fluid (aCSF) served as the vehicle and volume control.

Isolation of Total RNA and Reverse Transcription–Polymerase Chain Reaction
Isolation and extraction of total RNA from the ventrolateral part of medulla oblongata, at the level of the RVLM (0.5 to 2.5 mm rostral to the obex), and reverse transcription-polymerase chain reaction (RT-PCR) analysis of AT1R, AT2R, iNOS, or GAPDH mRNA were carried out as reported previously.21,24–26 The amount of mRNA product for AT1R, AT2R, or iNOS was analyzed by ImageMaster VDS analysis software (Amersham Pharmacia Biotech) and was expressed as the ratio to GAPDH mRNA product.

Protein Extraction and Western Blot Analysis
Western blot analysis was carried out with the use of a rabbit polyclonal antiserum against AT1R, AT2R, iNOS, or ß-tubulin (Santa Cruz) as the primary antiserum.27,28 This was followed by incubation with horseradish peroxidase–conjugated goat anti-rabbit IgG (Jackson). Specific antibody-antigen complex was detected with the use of an enhanced chemiluminescence Western blot detection system (NEN Life Science Products). The amount of AT1R, AT2R, or iNOS protein was quantified by Photo-Print Plus software (ETS Vilber-Lourmat) and was expressed as the ratio to ß-tubulin protein.

Experimental Scheme
Lipopolysaccharide (LPS, 15 mg/kg, serotype 0111:B4; Sigma) was administered intravenously to induce endotoxemia. Injection of the same amount of saline served as vehicle and volume control. Temporal changes in MSAP, HR, or power density of vasomotor components of the SAP signals were routinely followed for 8 hours. As we reported previously,4,29 these hemodynamic changes can be divided into 3 phases. We determined the expression profile of AT1R, AT2R, or iNOS, at mRNA or protein level, during Phase I and during early or late stages of Phases II and III endotoxemia. We also evaluated the cardiovascular responses to microinjection of ANG II or L-glutamate into the RVLM during these 5 phases. A causative role for NO produced by iNOS in these events was further investigated by pretreatment with bilaterally microinjected SMT into the RVLM.

Statistical Analysis
All values are expressed as mean±SEM. One-way or 2-way ANOVA with repeated measures was used to assess group means, as appropriate, to be followed by the Scheffé multiple range test for post hoc assessment of individual means. A value of P<0.05 was considered statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Temporal Changes in Cardiovascular Parameters During Experimental Endotoxemia
Intravenous injection of LPS (15 mg/kg) resulted in distinct temporal changes4,29 in MSAP, HR, or the power density of vasomotor components of SAP signals, our experimental index for sympathetic vasomotor outflow. The sequence of cardiovascular events can be divided into 3 phases (Figure 1). Phase I endotoxemia manifested a significant reduction in MSAP and the power density of vasomotor components of SAP spectrum, which occurred immediately after LPS administration. Phase II exhibited a rebound increase in MSAP, alongside a significant reversal of the depressed vasomotor spectral signals to an increase in power density. This was followed by Phase III, which was characterized by a significant secondary decrease in MSAP and the power density of the vasomotor components of SAP signals, together with bradycardia. At the dose of LPS used, Phase III endotoxemia persisted until termination of our experiment 8 hours after administration of the endotoxin. Of note was that the manifested cardiovascular depression during this phase was significantly attenuated on pretreatment with bilateral microinjection of a selective iNOS inhibitor, SMT (250 pmol), into the RVLM, delivered immediately before animals received LPS treatment.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 1. Time course changes in MSAP, HR, or total power density of vasomotor components (0 to 0.8 Hz) in SAP spectrum in rat that received intravenous administration of LPS (15 mg/kg; at arrow) or saline. These animals received, in addition, bilateral microjection into the RVLM of SMT (250 pmol) or aCSF, given immediately before LPS treatment. Values are mean±SEM, n=6 to 7 animals in each group. *P<0.05 vs corresponding (aCSF+saline) group; #P<0.05 vs corresponding (aCSF+LPS) in Scheffé multiple range test.

Downregulation of AT1R or Upregulation of iNOS in the Ventrolateral Medulla During Experimental Endotoxemia
RT-PCR analysis of tissue samples from the ventrolateral medulla that contains the bilateral RVLM (Figure 2) showed that the basal level of AT1R mRNA was significantly higher than that of AT2R mRNA (P<0.05 in quadruplicate analyses). There was also a progressive reduction in AT1R but not AT2R mRNA expression in the ventrolateral medulla during experimental endotoxemia. Of note was that the significant downregulation of AT1R mRNA, first detected during late Phase II endotoxemia, persisted throughout Phase III. Superimposed on a low but detectable basal expression of iNOS mRNA in the ventrolateral medulla,4–6,21 there was also a significant augmentation of iNOS mRNA expression4 that commenced at Phase I, followed by a progressive increase during Phase II and III endotoxemia (Figure 2).



View larger version (26K):
[in this window]
[in a new window]
 
Figure 2. Representative gels for RT-PCR products (insets) or amount of AT1R, AT2R, or iNOS mRNA relative to GAPDH mRNA, detected from ventrolateral medulla under basal condition (control) or at various phases after intravenous administration of LPS (15 mg/kg) or saline. Values are mean±SEM of triplicate analyses on samples pooled from 6 to 7 animals in each group. *P<0.05 vs corresponding saline group in Scheffé multiple range test.

Western blot analysis revealed comparable changes, with a time lag of {approx}45 minutes, in protein expression of AT1R, AT2R, or iNOS in the ventrolateral medulla during experimental endotoxemia (Figure 3). A significant reduction in the protein level of AT1R but not AT2R was observed at Phase III endotoxemia, along with a progressive surge of iNOS protein in the ventrolateral medulla during Phase II and III endotoxemia.



View larger version (26K):
[in this window]
[in a new window]
 
Figure 3. Representative gels for Western blot analysis (insets) or amount of AT1R, AT2R, or iNOS protein relative to ß-tubulin, detected from ventrolateral medulla under basal condition (control) or at various phases after intravenous administration of LPS (15 mg/kg) or saline. Values are mean±SEM of triplicate analyses on samples pooled from 6 to 7 animals in each group. *P<0.05 vs corresponding saline group in Scheffé multiple range test.

Reversal by iNOS Inhibitor of Downregulation of AT1R in the Ventrolateral Medulla During Experimental Endotoxemia
Bilateral microinjection into the RVLM of a selective iNOS inhibitor, SMT (250 pmol), delivered immediately before animals received LPS treatment significantly reversed the reduction of AT1R mRNA (Figure 4A) or protein (Figure 4B) expression in the ventrolateral medulla during endotoxemia. The same pretreatment, however, did not appreciably affect the basal mRNA or protein level of AT1R or AT2R in the ventrolateral medulla (data not shown).



View larger version (49K):
[in this window]
[in a new window]
 
Figure 4. Amount of AT1R mRNA relative to GAPDH mRNA (A) or AT1R protein relative to ß-tubulin (B), detected from ventrolateral medulla under basal condition (control) or at various phases after intravenous administration of LPS (15 mg/kg) or saline. These animals received in addition bilateral microinjection into the RVLM of SMT (250 pmol) or aCSF given immediately before LPS treatment. Values are mean±SEM of triplicate analyses on samples pooled from 6 to 7 animals in each group. *P<0.05 vs corresponding (aCSF+saline) group; #P<0.05 vs corresponding (aCSF+LPS) group in Scheffé multiple range test.

Reduced Cardiovascular Responses to ANG II During Experimental Endotoxemia and Their Reversal by iNOS Blockade
Unilateral microinjection of ANG II (50 pmol) into the RVLM promoted a significant increase in MSAP, HR, or the power density of the vasomotor components of SAP signals (Figure 5). Whereas those ANG II–induced cardiovascular responses remained essentially unaltered in saline-treated control subjects, the magnitude of ANG II–promoted hypertension, tachycardia, or increase in sympathetic vasomotor outflow underwent a significant reduction that began at late Phase II and persisted throughout Phase III endotoxemia. Pretreatment with local application of SMT (250 pmol) into the RVLM again significantly reversed these progressive manifestations of reduced cardiovascular responses to ANG II (Figure 6).



View larger version (39K):
[in this window]
[in a new window]
 
Figure 5. Time course changes in MSAP, HR, or total power density of vasomotor components (0 to 0.8 Hz) in SAP spectrum in rat that received intravenous administration of LPS (15 mg/kg) or saline. These animals received in addition unilateral microinjection into the RVLM of ANG II (50 pmol) or aCSF given at various phases after LPS or saline treatment. Values are mean±SEM, n=6 to 7 animals in each group. *P<0.05 vs corresponding (aCSF+saline) group; #P<0.05 vs corresponding (ANG II+saline) group in Scheffé multiple range test.



View larger version (44K):
[in this window]
[in a new window]
 
Figure 6. Time course changes in MSAP, HR, or total power density of vasomotor components (0 to 0.8 Hz) in SAP spectrum in rat that received intravenous administration of LPS (15 mg/kg) or saline. These animals received in addition bilateral microinjection into the RVLM of SMT (250 pmol) or aCSF given immediately before LPS treatment, followed by ANG II (50 pmol/L) at various phases after LPS treatment. Values are mean±SEM, n=6 to 7 animals in each group. *P<0.05 vs corresponding (aCSF+ANG II+saline) group; #P<0.05 vs corresponding (aCSF+ANG II+LPS) group in Scheffé multiple range test.

Lack of Changes in Cardiovascular Responses to L-Glutamate During Experimental Endotoxemia
Unilateral microinjection into the RVLM of L-glutamate (1 nmol) resulted in an increase in MSAP, HR, or the power density of the vasomotor components of SAP signals (Figure 7). These cardiovascular excitatory effects of l-glutamate were not significantly altered over a period of 8 hours after administration of LPS.



View larger version (39K):
[in this window]
[in a new window]
 
Figure 7. Time course changes in MSAP, HR, or total power density of vasomotor components (0 to 0.8 Hz) in SAP spectrum in rat that received intravenous administration of LPS (15 mg/kg) or saline. These animals received in addition unilateral microinjection into the RVLM of L-glutamate (L-Glu, 1 nmol) or aCSF, given at various phases after LPS or saline treatment. Values are mean±SEM, n=6 to 7 animals in each group. *P<0.05 vs corresponding (aCSF+saline) group in Scheffé multiple range test.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The current study demonstrated that a downregulation of both molecular synthesis and functional expression of AT1R in the RVLM, alongside reduction in sympathetic vasomotor tone, hypotension, or bradycardia, takes place during LPS-induced endotoxemia. We further showed that this downregulation of AT1R is consequential to the overproduction of NO through activation of iNOS in the RVLM during experimental endotoxemia.

In vitro observations on smooth muscle cells indicated that NO donors suppress AT1R expression at both mRNA and protein levels under normal conditions16,17 or during sepsis.18 The current study provided novel results to suggest that comparable cellular and molecular events took place at the RVLM during experimental endotoxemia. Similar to our previous observations,4,29 intravenous administration of LPS elicited a robust and progressive increase in iNOS mRNA and protein expression in the ventrolateral medulla. Intriguingly, this upregulation of molecular synthesis of iNOS was followed, after a time lag, by a decrease in both mRNA and protein levels of AT1R in the ventrolateral medulla, alongside reduced efficacy of ANG II to induce an increase in SAP, HR, or sympathetic vasomotor outflow on microinjection into the RVLM. More importantly, we established a causative relationship between the surge in iNOS-induced NO and reduction in AT1R expression in the RVLM during endotoxemia by demonstrating that pretreatment with microinjection of SMT bilaterally into the RVLM significantly reversed the downregulation of molecular synthesis and functional expression of AT1R at the ventrolateral medulla.

There are at least 2 ramifications of the downregulation of molecular synthesis and functional expression of AT1R at the RVLM during experimental endotoxemia. The first one relates to the reduction in sympathetic vasomotor outflow from the RVLM. The endogenous ANG II that originates from, for example, the paraventricular nucleus of hypothalamus,15 plays a critical role in the generation of tonic sympathetic vasomotor activity through activation of AT1R on RVLM neurons.12–15 On the other hand, we reported recently that NO produced by iNOS in the RVLM elicits sympathoinhibition4,5 through GABAergic neurotransmission.6 Furthermore, fatal cardiovascular depression associated with overproduction of NO in the RVLM during endotoxemia4,5 engages the formation of peroxynitrite.5 It follows that the progressive reduction in AT1R expression in the ventrolateral medulla that commenced at late stage of Phase II and persisted throughout Phase III endotoxemia would shift the balance in favor of sympathoinhibition, resulting in the significant cardiovascular depression seen during the last phase of experimental endotoxemia.

The second ramification relates to the maintained functional role of AT2R in the RVLM. We reported previously30 that ANG II exerts a tonic inhibition on baroreceptor reflex through an action on AT2R in the RVLM. Whereas this mode of action of ANG II is congruent with the sympathoexcitatory effect of the octapeptide through AT1R activation at the RVLM during hypertension,15 it is detrimental in the case of endotoxemia. We found that the molecular synthesis of AT2R at the RVLM did not undergo discernible changes during experimental endotoxemia. It is therefore conceivable that the maintained tonic inhibitory action of ANG II on the baroreceptor reflex through AT2R in the presence of retarded efficacy of the octapeptide to increase sympathetic vasomotor outflow because of the downregulated AT1R in the RVLM will exacerbate the impending cardiovascular depression during endotoxemia.

The mechanism that underlies transcriptional regulation of AT1R by NO during endotoxemia is not clear. Ichiki et al17 reported that downregulation of AT1R expression by NO may be attributable to a decrease in the activity of 2 unidentified DNA binding proteins that bind to the proximal promoter region of AT1R gene. In addition, both AP-1 and NF-{kappa}B in the upstream promoter region of the AT1R gene are potential consensus elements that may be regulated by NO.17,31 Whether these regulators are related to NO-induced downregulation of AT1R gene during endotoxemia, however, requires further delineation.

It is possible that the reduced cardiovascular excitatory effects of ANG II might be related to nonselective cytotoxicity because of the overproduction of iNOS-produced NO in the RVLM during experimental endotoxemia. This possibility of reduced responsiveness of RVLM neurons is deemed unlikely, since the increase in SAP, HR, or sympathetic vasomotor outflow induced by microinjection of L-glutamate into the RVLM was not appreciably altered during the entire course of endotoxemia. It is also possible that cardiovascular depression induced by NO overproduction in the RVLM during endotoxemia indirectly affects AT1R. In this regard, preliminary results indicated that reducing SAP to levels comparable to Phase III endotoxemia by infusion of nitroprusside (10 µg · kg-1 · h-1) did not discernibly affect the cardiovascular responses to microinjection of ANG II (50 pmol) into the RVLM.

In conclusion, the current study revealed that a downregulation of the molecular synthesis and functional expression of AT1R in the RVLM induced by the overproduction of NO through iNOS activation may underlie the cardiovascular depression during endotoxemia.

Perspectives
Several studies16–18,31,32 reported the downregulation of AT1R activity in the peripheral blood vessels, heart, lung, kidney, and adrenal gland during sepsis. Together with our present novel findings of a downregulation of AT1R synthesis and activity in the RVLM by NO during experimental endotoxemia, it is likely that an interaction between ANG II and NO are of key importance in the manifestation of cardiovascular abnormality associated with sepsis. ANG II–NO interaction is also involved in the pathophysiology of abnormal vascular tone, vessel wall remodeling, renal injury, insulin resistance, and hyperlipidemia during hypertension.33 In addition, the RVLM is now known to be intimately related to the physiological processes of cardiovascular regulation and the pathological processes of sepsis and hypertension, with differential contributions by AT1R, AT2R, and NOS isoforms.4–6,9,10,12–18,21,29,30,32,33 As such, further delineation of the role of ANG II–NO interactions in, and the contribution of angiotensin subtype receptors or NOS isoforms to, central cardiovascular regulation at the RVLM should open a new vista in our search for cellular and molecular mechanisms that underlie hypertension and sepsis and novel therapeutic interventions.


*    Acknowledgments
 
This work was supported by the Academic Excellence Program (89-B-FAO8-1-4) from the Ministry of Education (J.Y.H.C. and S.H.H.C.) and research grant VGHKS92-49 from Kaohsiung Veterans General Hospital (J.Y.H.C.), and NSC-91-2320-B075B-001 (J.Y.H.C.) from the National Science Council, Taiwan, Republic of China. S.H.H.C. is National Chair Professor of Neuroscience, appointed by the Ministry of Education.

Received February 28, 2003; first decision March 17, 2003; accepted May 9, 2003.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993; 328: 1471–1478.[Free Full Text]

2. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991; 43: 109–142.[Medline] [Order article via Infotrieve]

3. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A. 1995; 92: 10359–10363.[Abstract/Free Full Text]

4. Chan JYH, Wang SH, Chan SHH. Differential roles of iNOS and nNOS at rostral ventrolateral medulla during experimental endotoxemia in the rat. Shock. 2001; 15: 65–72.[Medline] [Order article via Infotrieve]

5. Chan SHH, Wang LL, Ou CC, Chan JYH. Contribution of peroxynitrite to fatal cardiovascular depression induced by overproduction of nitric oxide in rostral ventrolateral medulla of the rat. Neuropharmacology. 2002; 43: 889–898.[CrossRef][Medline] [Order article via Infotrieve]

6. Chan SHH, Wang LL, Chan JYH. Differential engagement of glutamate and GABA receptors in cardiovascular actions of endogenous nNOS or iNOS at rostral ventrolateral medulla of rats. Br J Pharmacol. 2003; 138: 584–593.[CrossRef][Medline] [Order article via Infotrieve]

7. Spyer KM. Central nervous mechanisms contributing to cardiovascular control. J Physiol. 1994; 474: 1–19.[Free Full Text]

8. Ross CA, Ruggiero DA, Park DH, Joh TH, Sved AF, Fernandez-Pardal J, Saavedra JM, Reis DJ. Tonic vasomotor control by the rostral ventrolateral medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline neurons on arterial pressure, heart rate, and plasma catecholamine and vasopressin. J Neurosci. 1984; 4: 474–494.[Abstract]

9. Sasaki S, Dampney RAL. Tonic cardiovascular effects of angiotensin II in the ventrolateral medulla. Hypertension. 1990; 15: 274–283.[Abstract/Free Full Text]

10. Hirooka Y, Potts PD, Dampney RAL. Role of angiotensin II receptor subtypes in mediating the sympathoexcitatory effects of exogenous and endogenous angiotensin peptides in the rostral ventrolateral medulla of the rabbit. Brain Res. 1997; 772: 107–114.[CrossRef][Medline] [Order article via Infotrieve]

11. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45: 205–251.[Medline] [Order article via Infotrieve]

12. Averill DB, Tsuchihashi T, Khosla MC, Ferrario CM. Losartan, nonpeptide angiotensin II-type 1 (AT1) receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II and L-glutamate in rostral ventrolateral medulla. Brain Res. 1994; 665: 245–252.[CrossRef][Medline] [Order article via Infotrieve]

13. Ito S, Sved AF. Blockade of angiotensin receptors in rat rostral ventrolateral medulla removes excitatory vasomotor tone. Am J Physiol. 1996; 270: R1317–R1323.[Medline] [Order article via Infotrieve]

14. DiBona G, Jones SY. Sodium intake influences hemodynamic and neural responses to angiotensin receptor blockade in rostral ventrolateral medulla. Hypertension. 2001; 37: 1114–1123.[Abstract/Free Full Text]

15. Ito S, Komatsu K, Tsukamoto K, Kanmatsuse K, Sved AF. Ventrolateral medulla AT1 receptors support blood pressure in hypertensive rats. Hypertension. 2002; 40: 552–559.[Abstract/Free Full Text]

16. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II–induced migration of rat aortic smooth muscle cell: role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest. 1995; 96: 141–149.[Medline] [Order article via Infotrieve]

17. Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshita A. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension. 1998; 31: 342–348.[Abstract/Free Full Text]

18. Bucher M, Ittner KP, Hobbhahn J, Taeger K, Kurtz A. Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension. 2001; 38: 177–182.[Abstract/Free Full Text]

19. Yang CH, Shyr MH, Kuo TBJ, Tan PPC, Chan SHH. Effects of propofol on nociceptive response and power spectra of electroencephalographic and systemic arterial pressure signals in the rat: correlation with plasma concentration. J Pharmacol Exp Ther. 1995; 275: 1568–1574.[Abstract/Free Full Text]

20. Kuo TBJ, Yang CHH, Chan SHH. Selective activation of vasomotor component of SAP spectrum by nucleus reticularis ventrolateralis in rats. Am J Physiol. 1997; 272: H458–H492.

21. Chan JYH, Wang LL, Wu KLH, Chan SHH. Reduced functional expression and molecular synthesis of inducible nitric oxide synthase in rostral ventrolateral medulla of spontaneously hypertensive rats. Circulation. 2001; 104: 1676–1681.[Abstract/Free Full Text]

22. Moore PK, Handy RLC. Selective inhibitors of neuronal nitric oxide synthase: is no NOS really good NOS for the nervous system? Trends Pharmacol Sci. 1997; 18: 204–211.[Medline] [Order article via Infotrieve]

23. Len WB, Chan SHH, Chan JYH. Parabrachial nucleus induces suppression of baroreflex bradycardia by the release of glutamate in the rostral ventrolateral medulla of the rat. J Biomed Sci. 2000; 7: 401–411.[CrossRef][Medline] [Order article via Infotrieve]

24. Chan JYH, Wang LL, Lee SY, Chan SHH. Augmented upregulation by c-fos of angiotensin subtype 1 receptor in nucleus tractus solitarii of spontaneously hypertensive rats. Hypertension. 2002; 40: 335–341.[Abstract/Free Full Text]

25. Hutchinson HG, Hein L, Fujinaga M, Pratt RE. Modulation of vascular development and injury by angiotensin II. Cardiovasc Res. 1999; 41: 689–700.[Abstract/Free Full Text]

26. Wang LL, Chan SHH, Chan JYH. Fos protein is required for the re-expression of angiotensin II type 1 receptors in the nucleus tractus solitarii after baroreceptor activation in the rat. Neuroscience. 2001; 103: 143–151.[CrossRef][Medline] [Order article via Infotrieve]

27. Li PL, Chao YM, Chan SHH, Chan JYH. Potentiation of baroreceptor reflex response by heat shock protein 70 in nucleus tractus solitarii confers cardiovascular protection during heatstroke. Circulation. 2001; 103: 2114–2119.[Abstract/Free Full Text]

28. Chan SHH, Chang KF, Ou CC, Chan JYH. Up-regulation of glutamate receptors in nucleus tractus solitarii underlies potentiation of baroreceptor reflex by heat shock protein 70. Mol Pharmacol. 2002; 61: 1097–1104.[Abstract/Free Full Text]

29. Chuang YC, Tsai JL, Chang AYW, Chan JYH, Liou CW, Chan SHH. Dysfunction of mitochondrial respiratory chain in rostral ventrolateral medulla during experimental endotoxemia in the rat. J Biomed Sci. 2002; 9: 542–548.[Medline] [Order article via Infotrieve]

30. Lin KS, Chan SHH, Chan JYH. Tonic suppression of spontaneous baroreceptor reflex by endogenous angiotensins via AT2 subtype receptors at nucleus reticularis ventrolateralis in the rat. Synapse. 2001; 40: 85–94.[CrossRef][Medline] [Order article via Infotrieve]

31. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A. 1996; 93: 9114–9119.[Abstract/Free Full Text]

32. Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A. Regulation of angiotensin II receptors expression by nitric oxide in rat adrenal gland. Hypertension. 1998; 32: 527–533.[Abstract/Free Full Text]

33. Raij L. Hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001; 37: 767–773.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
F. Sayk, A. Vietheer, B. Schaaf, P. Wellhoener, G. Weitz, H. Lehnert, and C. Dodt
Endotoxemia causes central downregulation of sympathetic vasomotor tone in healthy humans
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R891 - R898.
[Abstract] [Full Text] [PDF]


Home page
Innate ImmunityHome page
Z. Shariat-Madar and A. H. Schmaier
Review: The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis
Innate Immunity, February 1, 2004; 10(1): 3 - 13.
[Abstract] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
42/1/103    most recent
01.HYP.0000077984.85616.23v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, J. Y.H.
Right arrow Articles by Chan, S. H.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, J. Y.H.
Right arrow Articles by Chan, S. H.H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLUTAMIC ACID HYDROCHLORIDE
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Physiological and pathological control of gene expression
Right arrow Autonomic, reflex, and neurohumoral control of circulation